Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.neulandlabs.com | |
Market Cap | 8,960.20 Cr. | |
Enterprise Value(EV) | 8,919.15 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 247.13 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 28.26 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.99 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 945.65 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 7.39 | Calculated using Price: 6,983.85 |
Dividend Yield | 0.14 | Period Ending 2023-03 |
No. of Shares Subscribed | 1.28 Cr. | 12,829,889 Shares |
FaceValue | 10 | |
About Neuland Laboratories Ltd. | ||
Neuland is a quality conscious, research driven, reliable source of active pharmaceutical ingredients. Neuland has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions. Safety aspects have been given utmost significance may it be plant installation, equipment, systems and personnel to ensure smooth productivity. Dedicated team of manufacturing with incorporation of latest production techniques guarantees delivery of latest intermediate and product to our customers across the globe. |
1 Day |
|
-1.67% |
1 Week |
|
-8.92% |
1 Month |
|
+9.22% |
3 Month |
|
+14.40% |
6 Month |
|
+84.30% |
1 Year |
|
+248.78% |
2 Year |
|
+412.75% |
5 Year |
|
+899.84% |
10 Year |
|
+2593.58% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 11.24 | 15.64 | 22.34 | 5.02 | 3.48 | 2.3 | 10.79 | 7.85 | 17.84 | |
Return on Capital Employed (%) | 15.75 | 18.57 | 15.98 | 4.07 | 3.99 | 7.85 | 12.81 | 9.44 | 20.94 | |
Return on Assets (%) | 3.2 | 5.23 | 6.65 | 1.23 | 1.49 | 1.37 | 6.31 | 4.71 | 11.04 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 161 | 187 | 546 | 558 | 699 | 710 | 786 | 841 | 994 | 1,133 | |
Non Curr. Liab. | 55 | 69 | 54 | 146 | 104 | 163 | 170 | 180 | 147 | 129 | |
Curr. Liab. | 295 | 268 | 286 | 367 | 327 | 358 | 369 | 363 | 439 | 403 | |
Minority Int. | 0 | ||||||||||
Equity & Liab. | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,580 | 1,665 | |
Non Curr. Assets | 196 | 210 | 511 | 624 | 677 | 716 | 775 | 803 | 819 | 831 | |
Curr. Assets | 316 | 314 | 375 | 447 | 453 | 515 | 550 | 581 | 761 | 834 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,580 | 1,665 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 469 | 510 | 579 | 527 | 667 | 763 | 937 | 951 | 1,191 | 1,581 | |
Other Income | 1 | 2 | 1 | 5 | 3 | 4 | 16 | 2 | 10 | 15 | |
Total Income | 470 | 512 | 580 | 532 | 670 | 767 | 953 | 953 | 1,201 | 1,596 | |
Total Expenditure | -403 | -430 | -473 | -477 | -608 | -661 | -790 | -808 | -919 | -1,105 | |
PBIDT | 67 | 82 | 108 | 55 | 62 | 106 | 163 | 145 | 282 | 491 | |
Interest | -27 | -24 | -21 | -19 | -16 | -22 | -18 | -14 | -13 | -15 | |
Depreciation | -15 | -16 | -19 | -22 | -26 | -31 | -40 | -49 | -53 | -57 | |
Taxation | -9 | -15 | -20 | -2 | -4 | -37 | -25 | -18 | -52 | -102 | |
Exceptional Items | |||||||||||
PAT | 16 | 27 | 47 | 12 | 16 | 16 | 81 | 64 | 164 | 317 | |
Minority Interest | 0 | 0 | |||||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 16 | 27 | 47 | 12 | 16 | 16 | 81 | 64 | 164 | 317 | |
Adjusted EPS | 18 | 31 | 53 | 14 | 13 | 13 | 63 | 50 | 127 | 246 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 49 | 13 | 45 | 39 | 11 | 70 | 57 | 189 | 60 | 237 | |
Cash Fr. Inv. | -10 | -14 | -20 | -42 | -116 | -77 | -49 | -84 | -96 | -62 | |
Cash Fr. Finan. | -39 | 1 | -24 | 0 | 105 | 12 | -5 | -114 | 38 | -136 | |
Net Change | 0 | 0 | 1 | -4 | 0 | 5 | 3 | -9 | 3 | 40 | |
Cash & Cash Eqvt | 1 | 1 | 2 | 3 | 3 | 8 | 11 | 2 | 5 | 45 |
Tue, 23 Apr 2024
Board Meeting Intimation NEULAND LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 10-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2024 and Dividend. |
Mon, 08 Apr 2024
Disclosure under SEBI Takeover Regulations Neuland Laboratories Limitedᅡᅠhas Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of Indiaᅡᅠ(Substantial Acquisition of Shares and Takeovers) Regulations, 2011. |
Wed, 03 Apr 2024
Certificate under SEBI (Depositories and Participants) Regulations, 2018 Neuland Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |
Fri, 26 Apr 2024 |
Closing Below Previous Low |
Closing Below Previous Low for 3 days |
Making Lower Lows for 3 days |
Close Within 52 Week High Zone |
Closing Below Previous Low for 2 Days |